Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis

Marka Van Blitterswijk, Sunita Gulati, Elizabeth Smoot, Matthew Jaffa, Nancy Maher, Bradley T. Hyman, Adrian J. Ivinson, Clemens R. Scherzer, David A. Schoenfeld, Merit E. Cudkowicz, Robert H. Brown, Daryl A. Bosco

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Our objective was to test the hypothesis that aberrantly modified forms of superoxide dismutase (SOD1) influence the disease course for sporadic amyotrophic lateral sclerosis (SALS). We probed for anti-SOD1 antibodies (IgM and IgG) against both the normal and aberrantly oxidized-SOD1 (SODox) antigens in sera from patients with SALS, subjects diagnosed with other neurological disorders and healthy individuals, and correlated the levels of these antibodies to disease duration and/or severity. Anti-SOD1 antibodies were detected in all cohorts; however, a subset of ∼510% of SALS cases exhibited elevated levels of anti-SOD1 antibodies. Those SALS cases with relatively high levels of IgM antibodies against SODox exhibit a longer survival of 6.4 years, compared to subjects lacking these antibodies. By contrast, SALS subjects expressing higher levels of IgG antibodies reactive for the normal WT-SOD1 antigen exhibit a shorter survival of 4.1 years. Anti-SOD1 antibody levels did not correlate with disease severity in either the Alzheimer's or Parkinson's disease cohorts. In conclusion, the association of longer survival with elevated levels of anti-SODox antibodies suggests that these antibodies may be protective. By extension, these data implicate aberrantly modified forms of WT-SOD1 (e.g. oxidized SOD1) in SALS pathogenesis. In contrast, an immune response against the normal WT-SOD1 appears to be disadvantageous in SALS, possibly because the anti-oxidizing activity of normal WT-SOD1 is beneficial to SALS individuals.

Original languageEnglish (US)
Pages (from-to)430-438
Number of pages9
JournalAmyotrophic Lateral Sclerosis
Volume12
Issue number6
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Sclerosis
Superoxide Dismutase
Survival
Antibodies
Anti-Idiotypic Antibodies
Immunoglobulin M
Immunoglobulin G
Antigens
Amyotrophic lateral sclerosis 1
Nervous System Diseases
Parkinson Disease
Alzheimer Disease
Serum

Keywords

  • alzheimer's disease
  • immunotherapy
  • parkinson's disease
  • Sporadic amyotrophic lateral sclerosis
  • superoxide dismutase

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis. / Van Blitterswijk, Marka; Gulati, Sunita; Smoot, Elizabeth; Jaffa, Matthew; Maher, Nancy; Hyman, Bradley T.; Ivinson, Adrian J.; Scherzer, Clemens R.; Schoenfeld, David A.; Cudkowicz, Merit E.; Brown, Robert H.; Bosco, Daryl A.

In: Amyotrophic Lateral Sclerosis, Vol. 12, No. 6, 11.2011, p. 430-438.

Research output: Contribution to journalArticle

Van Blitterswijk, M, Gulati, S, Smoot, E, Jaffa, M, Maher, N, Hyman, BT, Ivinson, AJ, Scherzer, CR, Schoenfeld, DA, Cudkowicz, ME, Brown, RH & Bosco, DA 2011, 'Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis', Amyotrophic Lateral Sclerosis, vol. 12, no. 6, pp. 430-438. https://doi.org/10.3109/17482968.2011.585163
Van Blitterswijk, Marka ; Gulati, Sunita ; Smoot, Elizabeth ; Jaffa, Matthew ; Maher, Nancy ; Hyman, Bradley T. ; Ivinson, Adrian J. ; Scherzer, Clemens R. ; Schoenfeld, David A. ; Cudkowicz, Merit E. ; Brown, Robert H. ; Bosco, Daryl A. / Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis. In: Amyotrophic Lateral Sclerosis. 2011 ; Vol. 12, No. 6. pp. 430-438.
@article{8559e33f8ece4dc5a49ffb0bff815afd,
title = "Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis",
abstract = "Our objective was to test the hypothesis that aberrantly modified forms of superoxide dismutase (SOD1) influence the disease course for sporadic amyotrophic lateral sclerosis (SALS). We probed for anti-SOD1 antibodies (IgM and IgG) against both the normal and aberrantly oxidized-SOD1 (SODox) antigens in sera from patients with SALS, subjects diagnosed with other neurological disorders and healthy individuals, and correlated the levels of these antibodies to disease duration and/or severity. Anti-SOD1 antibodies were detected in all cohorts; however, a subset of ∼510{\%} of SALS cases exhibited elevated levels of anti-SOD1 antibodies. Those SALS cases with relatively high levels of IgM antibodies against SODox exhibit a longer survival of 6.4 years, compared to subjects lacking these antibodies. By contrast, SALS subjects expressing higher levels of IgG antibodies reactive for the normal WT-SOD1 antigen exhibit a shorter survival of 4.1 years. Anti-SOD1 antibody levels did not correlate with disease severity in either the Alzheimer's or Parkinson's disease cohorts. In conclusion, the association of longer survival with elevated levels of anti-SODox antibodies suggests that these antibodies may be protective. By extension, these data implicate aberrantly modified forms of WT-SOD1 (e.g. oxidized SOD1) in SALS pathogenesis. In contrast, an immune response against the normal WT-SOD1 appears to be disadvantageous in SALS, possibly because the anti-oxidizing activity of normal WT-SOD1 is beneficial to SALS individuals.",
keywords = "alzheimer's disease, immunotherapy, parkinson's disease, Sporadic amyotrophic lateral sclerosis, superoxide dismutase",
author = "{Van Blitterswijk}, Marka and Sunita Gulati and Elizabeth Smoot and Matthew Jaffa and Nancy Maher and Hyman, {Bradley T.} and Ivinson, {Adrian J.} and Scherzer, {Clemens R.} and Schoenfeld, {David A.} and Cudkowicz, {Merit E.} and Brown, {Robert H.} and Bosco, {Daryl A.}",
year = "2011",
month = "11",
doi = "10.3109/17482968.2011.585163",
language = "English (US)",
volume = "12",
pages = "430--438",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic later sclerosis

AU - Van Blitterswijk, Marka

AU - Gulati, Sunita

AU - Smoot, Elizabeth

AU - Jaffa, Matthew

AU - Maher, Nancy

AU - Hyman, Bradley T.

AU - Ivinson, Adrian J.

AU - Scherzer, Clemens R.

AU - Schoenfeld, David A.

AU - Cudkowicz, Merit E.

AU - Brown, Robert H.

AU - Bosco, Daryl A.

PY - 2011/11

Y1 - 2011/11

N2 - Our objective was to test the hypothesis that aberrantly modified forms of superoxide dismutase (SOD1) influence the disease course for sporadic amyotrophic lateral sclerosis (SALS). We probed for anti-SOD1 antibodies (IgM and IgG) against both the normal and aberrantly oxidized-SOD1 (SODox) antigens in sera from patients with SALS, subjects diagnosed with other neurological disorders and healthy individuals, and correlated the levels of these antibodies to disease duration and/or severity. Anti-SOD1 antibodies were detected in all cohorts; however, a subset of ∼510% of SALS cases exhibited elevated levels of anti-SOD1 antibodies. Those SALS cases with relatively high levels of IgM antibodies against SODox exhibit a longer survival of 6.4 years, compared to subjects lacking these antibodies. By contrast, SALS subjects expressing higher levels of IgG antibodies reactive for the normal WT-SOD1 antigen exhibit a shorter survival of 4.1 years. Anti-SOD1 antibody levels did not correlate with disease severity in either the Alzheimer's or Parkinson's disease cohorts. In conclusion, the association of longer survival with elevated levels of anti-SODox antibodies suggests that these antibodies may be protective. By extension, these data implicate aberrantly modified forms of WT-SOD1 (e.g. oxidized SOD1) in SALS pathogenesis. In contrast, an immune response against the normal WT-SOD1 appears to be disadvantageous in SALS, possibly because the anti-oxidizing activity of normal WT-SOD1 is beneficial to SALS individuals.

AB - Our objective was to test the hypothesis that aberrantly modified forms of superoxide dismutase (SOD1) influence the disease course for sporadic amyotrophic lateral sclerosis (SALS). We probed for anti-SOD1 antibodies (IgM and IgG) against both the normal and aberrantly oxidized-SOD1 (SODox) antigens in sera from patients with SALS, subjects diagnosed with other neurological disorders and healthy individuals, and correlated the levels of these antibodies to disease duration and/or severity. Anti-SOD1 antibodies were detected in all cohorts; however, a subset of ∼510% of SALS cases exhibited elevated levels of anti-SOD1 antibodies. Those SALS cases with relatively high levels of IgM antibodies against SODox exhibit a longer survival of 6.4 years, compared to subjects lacking these antibodies. By contrast, SALS subjects expressing higher levels of IgG antibodies reactive for the normal WT-SOD1 antigen exhibit a shorter survival of 4.1 years. Anti-SOD1 antibody levels did not correlate with disease severity in either the Alzheimer's or Parkinson's disease cohorts. In conclusion, the association of longer survival with elevated levels of anti-SODox antibodies suggests that these antibodies may be protective. By extension, these data implicate aberrantly modified forms of WT-SOD1 (e.g. oxidized SOD1) in SALS pathogenesis. In contrast, an immune response against the normal WT-SOD1 appears to be disadvantageous in SALS, possibly because the anti-oxidizing activity of normal WT-SOD1 is beneficial to SALS individuals.

KW - alzheimer's disease

KW - immunotherapy

KW - parkinson's disease

KW - Sporadic amyotrophic lateral sclerosis

KW - superoxide dismutase

UR - http://www.scopus.com/inward/record.url?scp=80055044020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055044020&partnerID=8YFLogxK

U2 - 10.3109/17482968.2011.585163

DO - 10.3109/17482968.2011.585163

M3 - Article

VL - 12

SP - 430

EP - 438

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 6

ER -